Elicio Therapeutics Inc <ELTX.OQ> expected to post a loss of 51 cents a share - Earnings Preview
Elicio Therapeutics Inc ELTX.OQ ELTX.O is expected to show no change in quarterly revenue when it reports results for the period ending September 30 2025
LSEG's mean analyst estimate for Elicio Therapeutics Inc is for a loss of 51 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 3.3% in the last three months.
Wall Street's median 12-month price target for Elicio Therapeutics Inc is $12.50, about 26.4% above its last closing price of $9.20
This summary was machine generated August 9 at 00:28 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
